Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 1941 to 1950 of 2581 total matches.
Eroxon — An OTC Gel for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
for treatment of ED. The onset of
action is about 30-45 minutes for each of these drugs.
PDE5 inhibitors can ...
The FDA has authorized over-the-counter (OTC)
sale of a nonmedicated alcohol-based gel (Eroxon –
Futura) for treatment of erectile dysfunction (ED) in
males ≥22 years old. Eroxon is the only FDA-approved
OTC and topical treatment for erectile dysfunction. It
is also available in the UK and the EU.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):181-2 doi:10.58347/tml.2024.1715c | Show Introduction Hide Introduction
In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
disease. Med Lett Drugs Ther 2023; 65:155.
2. In brief: RSV vaccine (Arexvy) for ages 50-59. Med Lett ...
The FDA has required a new warning in the labels of the
recombinant respiratory syncytial virus (RSV) vaccines
Arexvy (GSK) and Abrysvo (Pfizer) about an increased
risk of Guillain-Barré syndrome (GBS) within 42 days
of administration of either vaccine. Both vaccines
are FDA-approved to prevent lower respiratory tract
disease (LRTD) caused by RSV in adults.Abrysvo is
also approved for use in pregnant women at 32-36
weeks' gestation to prevent RSV-associated LRTD in
their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):31-2 doi:10.58347/tml.2025.1722d | Show Introduction Hide Introduction
Penicillin Allergy
The Medical Letter on Drugs and Therapeutics • Aug 12, 1988 (Issue 772)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or some other reaction while taking a penicillin, but maculopapular rashes with ampicillin or amoxicillin, especially in children with infectious mononucleosis, are probably not allergic.
Aspirin For Prevention Of Myocardial Infarction And Stroke
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989 (Issue 799)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Taking aspirin to prevent recurrence or worsening of cardiovascular disease has become a common practice in recent years (Medical Letter, 28:31, 1986). Now, the US Food and Drug Administration is considering whether aspirin can also be advertised for prevention of a first myocardial infarction in previously healthy people.
Mifepristone (RU 486)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2000 (Issue 1091)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Mifepristone (RU 486; Mifeprex - Danco), an antiprogestin, has been approved by the FDA for termination of intrauterine pregnancies of 49 days or less. It is generally used with misoprostol (Cytotec - Searle), an E1 prostaglandin analog marketed in the USA only for prevention of gastric ulcers.
Budesonide (Entocort EC) For Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002 (Issue 1122)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Budesonide (Entocort EC AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19), has been approved for oral treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon. Both oral budesonide and budesonide enemas have been available for years in Europe and Canada for treatment of inflammatory bowel disease.
Zolmitriptan (Zomig) Nasal Spray for Migraine
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004 (Issue 1174)
sprays are more convenient
than subcutaneous injections.
TRIPTANS FOR MIGRAINE
Drug Usual dosage Cost ...
Zolmitriptan (Zomig - AstraZeneca) nasal spray was recently approved by the FDA for treatment of migraine. It is the second selective serotonin receptor agonist ("triptan") to become available as a nasal spray; sumatriptan has been available in this form since 1997. Some patients with migraine cannot take tablets because of nausea and vomiting, and nasal sprays are more convenient than subcutaneous injections.
Insulin-like Growth Factor-1 for Severe Growth Failure
The Medical Letter on Drugs and Therapeutics • May 20, 2007 (Issue 1261)
Letter
®
On Drugs and Therapeutics
Volume 49 (Issue 1261)
May 21, 2007
www.medicalletter.org ...
Mecasermin (Increlex - Tercica), which is injected subcutaneously, has been approved by the FDA for treatment of growth failure in children with severe primary insulin-like growth factor (IGF-1) deficiency. Mecasermin is recombinant human (rh) IGF-1. It has also been approved to treat children with short stature who are deficient in growth hormone (GH), but have developed neutralizing antibodies in response to GH treatment. A similar product, mecasermin rinfabate (Iplex - Insmed), that was approved by the FDA for the same indications was withdrawn from the market due to patent...
Resveratrol
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009 (Issue 1321)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Carbidopa/Levodopa Extended-Release Capsules (Rytary)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 57 (Issue ...
The FDA has approved a new formulation of carbidopa/levodopa (Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).